February 24, 2004
The monthly Patient Page discusses the risks of liver abnormalities while on interferon therapy for MS. â-interferon drugs are injected to help reduce the frequency of attacks. A study led by Helen L. Tremlett, PhD, of the University of British Columbia and Vancouver Hospital & Health Sciences Center, found nearly one-third of 835 MS patients treated with â-interferon drugs had higher alanine aminotransferases, which is associated with abnormal liver function. This is a higher incidence of elevated alanine aminotransferases than has been previously reported in interferon therapy for MS.
The Patient Page will be available for downloading from www.neurology.org
after the embargo, or can be obtained in advance from AAN media relations
Copyright © 2004, EurekAlert